Valuation: Scinai Immunotherapeutics Ltd.

Market Cap 954K 837K 775K 713K 1.35M 91.34M 1.38M 9.24M 3.62M 44.85M 3.58M 3.51M 155M P/E 2024 *
-
P/E 2025 -0.2x
Enterprise Value 1.56M 1.37M 1.27M 1.17M 2.21M 149M 2.25M 15.11M 5.93M 73.34M 5.86M 5.73M 253M EV / Sales 2024
4,521,684x
EV / Sales 2025 2,346,088x
Free-Float
0.36%
Yield 2024 *
-
Yield 2025 -
Jun. 15 Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
May. 20 Scinai Immunotherapeutics Ltd. Appoints Eilon Elmalem as Site Head of Yavne Cdmo Facility, Effective June 14, 2026 CI
Apr. 26 Scinai Immunotherapeutics Ltd. announced that it has received $2.5 million in funding CI
Apr. 23 Scinai Immunotherapeutics Ltd. announced that it expects to receive $2.5 million in funding CI
Apr. 06 Scinai completes strategic reorganization to establish dedicated CDMO platform and lean R&D structure; outlines 2026 priorities RE
Apr. 06 Scinai Immunotherapeutics Leverages Strategic Collaboration with Recipharm to Build Integrated Lifecycle CDMO Platform CI
Apr. 01 Scinai reports full-year 2025 results, with cdmo revenues doubling and strategic expansion through Recipharm collaboration RE
Apr. 01 Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Mar. 31 Scinai Immunotherapeutics Ltd. Auditor Raises 'Going Concern' Doubt CI
Mar. 16 Scinai Immunotherapeutics receives Nasdaq notification regarding minimum bid price RE
Mar. 02 Scinai signs second amendment to Pincell option agreement and submits revised EUR12 million non-dilutive Feng application to advance Pc111 through human proof of concept RE
Feb. 25 Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform CI
Feb. 17 Scinai Immunotherapeutics Ltd. acquired Recipharm Israel Ltd. from Recipharm AB. CI
1 day-3.87%
1 week-10.34%
Current month-4.59%
1 month-27.19%
3 months-59.29%
6 months-70.96%
Current year-66.16%
1 week 0.24
Extreme 0.2409
0.27
1 month 0.24
Extreme 0.2408
0.39
Current year 0.24
Extreme 0.2408
1.12
1 year 0.24
Extreme 0.2408
3.48
3 years 0.24
Extreme 0.2408
15.5
5 years 0.24
Extreme 0.2408
419
10 years 0.24
Extreme 0.2408
6,199.99
Manager TitleAgeSince
Chief Executive Officer 51 2021-03-01
Director of Finance/CFO 54 2006-12-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 77 2019-09-29
Director/Board Member 64 2020-03-23
Director/Board Member 71 2020-03-23
Date Insider Type Main position Quantity % Market Cap.
Jun. 15Free

Chief Executive Officer

400,000,000 1.9946%
Jun. 15Free

Chairman

120,000,000 0.5984%
Mar. 17Other

Director

58,120,000 1.7034%
Change 5-day change 1-year change 3-year change Capi.($)
-3.87%-10.34%-89.59%-98.38% 954K
-0.93%+1.50%+3.26%+7.09% 50.61B
-1.57%-3.18%+383.82%+593.37% 39.11B
-0.14%+0.77%+27.49%-5.50% 34.64B
+1.76%-1.78%+21.44%+53.38% 33.79B
-0.06%-0.45%+2.94%+28.70% 26.89B
-1.93%-1.01% - - 16.47B
-1.49%-6.18%+63.89%+120.53% 15.14B
-1.50%-0.67%+13.80%+16.03% 13.85B
-0.97%-2.83%+10.35%-33.29% 12.72B
Average -1.07%-2.37%+48.60%+75.77% 24.32B
Weighted average by Cap. -0.59%-1.08%+80.36%+121.60%

Financials

2024 2025
Net sales 0.66 0.58 0.53 0.49 0.93 62.98 0.95 6.37 2.5 30.93 2.47 2.42 106.81 1.31 1.15 1.07 0.98 1.85 125.48 1.89 12.69 4.98 61.62 4.92 4.82 212.8
Net income 4.8M 4.21M 3.9M 3.58M 6.78M 459M 6.91M 46.44M 18.21M 225M 18.01M 17.62M 778M -8.31M -7.29M -6.75M -6.21M -11.74M -795M -11.97M -80.43M -31.55M -390M -31.19M -30.51M -1.35B
Net Debt 122K 107K 99.11K 91.19K 172K 11.68M 176K 1.18M 463K 5.73M 458K 448K 19.8M 606K 532K 492K 453K 857K 58M 873K 5.87M 2.3M 28.48M 2.28M 2.23M 98.37M
Logo Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Employees
45
Date Price Change Volume
26-07-13 $0.2410 -3.87% 87,799
26-07-10 $0.2507 -2.83% 38,930
26-07-09 $0.2580 -4.44% 91,826
26-07-08 $0.2700 +4.69% 103,632
26-07-07 $0.2579 -4.06% 97,497

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCNI Stock